European Pharmaceutical Review

SEPTEMBER 12, 2023

A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. percent with chemotherapy. The cancer vaccine offered an overall survival of 11.1 months for chemotherapy.

Vaccines 98

Vaccines Chemotherapy Immunization 98

European Pharmaceutical Review

JANUARY 10, 2024

A lymph node-targeted cancer vaccine has shown potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers in patients who have had surgery, according to a Phase I trial led by US researchers. Patients were given no more than 10 doses of the ELI-002 cancer vaccine targeted toward KRAS G12D and G12R mutations. “It

Vaccines 98

Vaccines Chemotherapy 98

Hospital Pharmacy Europe

OCTOBER 14, 2024

The idea of cancer vaccines is not new, but Dr Victoria Kunene, consultant medical oncologist at Queen Elizabeth Hospital Birmingham, UK, is leading the charge in their latest iteration: personalised preventative and therapeutic mRNA vaccines against colorectal cancer.

Vaccines 52

Vaccines Chemotherapy Hospitals Immunization 52

pharmaphorum

SEPTEMBER 16, 2021

The US regulator has cleared the tyrosine kinase inhibitor (TKI) as a second-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumours have EGFR exon20 insertion mutations, after first-line chemotherapy.

FDA 105

FDA Chemotherapy Vaccines 105

PQA

NOVEMBER 1, 2024

We are excited to host members next week at the 2024 PQA Leadership Summit and PQA Convenes: Quality Medication Use in Rare Disease at the Renaissance Arlington Capital View Hotel in Arlington, Va. We also highlight our members' perspectives on health outcomes, oral oncolytics and vaccination recommendations.

Specialty Pharmacies 52

Specialty Pharmacies Vaccines Chemotherapy Immunization 52

European Pharmaceutical Review

JUNE 27, 2023

difficile infection by the end of 2024 and will be announcing first patient dosed in the Phase II clinical trial of VE202 for ulcerative colitis (UC) shortly too. How do you envision microbiome therapies complementing existing cancer treatments, such as chemotherapy and immunotherapy?

Chemotherapy 105

Chemotherapy Immunization FDA Vaccines 105

Pharmaceutical Technology

JUNE 13, 2023

The company aims to then increase supplies in 2024. Common treatment options for the condition include bladder removal surgery, chemotherapy and/or administration of the BCG vaccine in the bladder. Ferring plans to begin Adstiladrin production in the H2 2023, as part of an initial rollout in the US.

FDA 98

FDA Vaccines Chemotherapy Communication 98